SCHEDULE: BlackRock Discloses 5.3% Stake in Aquestive Therapeutics

BlackRock, Inc. has reported a 5.3% beneficial ownership stake in Aquestive Therapeutics Inc., holding over 6.4 million common shares.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating beneficial ownership of Aquestive Therapeutics Inc. common stock.
• The filing reports BlackRock's aggregate beneficial ownership of 6,426,343 shares, representing 5.3% of the class.
• BlackRock holds sole voting power over 6,290,838 shares and sole dispositive power over 6,426,343 shares.
• No shared voting or dispositive power is reported.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Aquestive Therapeutics Inc.
• Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Financial Management, Inc., are identified as entities through which beneficial ownership is held, with at least one beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership by a passive investor, containing no explicit positive or negative operational news for the issuer. The sentiment is neutral, reflecting standard regulatory compliance.

Positives

• The disclosure of a significant stake by a major institutional investor like BlackRock can be perceived as a positive signal of confidence in Aquestive Therapeutics Inc.'s long-term prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Aquestive Therapeutics Inc.'s future performance or outlook, as it is a disclosure of beneficial ownership by an institutional investor.

Industry Context

This filing reflects routine institutional investment activity where large asset managers like BlackRock disclose their passive stakes in publicly traded companies. Such disclosures are common and provide transparency into significant ownership positions, which can influence market perception of a company's stability and investment appeal.

Comparison to Industry Standards

• Not applicable for a beneficial ownership disclosure filing, as this document does not report company performance or operational results.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a prominent institutional investor like BlackRock may instill confidence among existing shareholders and potentially attract new investors, signaling institutional validation of the company.

Key Dates

Keywords

Aquestive Therapeutics, BlackRock, Institutional Ownership, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, AQST